Clinical Trial

Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry

Study acronym: ACHIEVE-SGLT2i
Recruiting
View on ClinicalTrials.gov →
Summary
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-09; most recent amendment 2026-02-11.
Trial Details
NCT Number NCT06932081
Lead Sponsor Leiden University Medical Center
Conditions Adult Congenital Heart Disease, Congenital Heart Disease, Systemic Right Ventricle, Transposition of the Great Arteries, Congenitally Corrected Transposition of the Great Arteries, Fontan, Single Ventricle, Tetralogy of Fallot (TOF)
Enrollment 400 participants
Start Date 2023-01-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-13